Skip to main content
. 2020 Jan 1;11(5):1063–1074. doi: 10.7150/jca.35659

Table 3.

Baseline demographics and clinical characteristics of the propensity score matching (PSM) cohort (n=542) and the independent cohort (n=150).

Characteristics PSM cohort, n (%) Independent cohort, n (%)
Total 542(100.0) 150(100.0)
Age, years (median/IQR) 53(43-62) 61(51-67)
Gender
Male 346(63.8) 88 (58.7)
Female 196(36.2) 62(41.3)
ECOG PS score
0 325(60.0) 22(14.7)
1-2 217(40.0) 128(85.3)
Primary tumor site
Right 137(25.3) 32(21.3)
Left 405(74.7) 118(78.7)
Tumor grade
G1-2 415(76.6) 112(74.7)
G3 127(23.4) 38(25.3)
Number of metastatic organs
1 221(40.8) 102(68.0)
≥2 321(59.2) 48(32.0)
Primary/Metastatic tumor resection
No 284(52.4) 43(28.7)
Yes 258(47.6) 107(71.3)
Chemotherapy
Chemo alone 390(72.0) 104(69.3)
Combination 152(28.0) 46(30.7)
CEA (ng/ml)
>5 340(62.7) 105(70.0)
≤5 202(37.3) 45(30.0)
CA19-9(ng/ml)
>35 235(43.4) 67(44.7)
≤35 307(56.6) 83(55.3)
Cholesterols (mmol/L)
>6.47 45(8.3) 18(12.0)
≤6.47 497(91.7) 132(88.0)
Triglycerides (mmol/L)
>1.70 116(21.4) 24(16.0)
≤1.70 426(78.6) 126(84.0)
HDL-C (mmol/L)
≥0.78 481(88.7) 140(93.3)
<0.78 61(11.3) 10(6.7)
LDL-C (mmol/L)
>3.40 186(34.3) 53(35.3)
≤3.40 356(65.7) 97(64.7)
ApoA-I (ng/L)
≥1.05 362(66.8) 49(32.7)
<1.05 180(33.2) 101(67.3)
ApoB (ng/L)
>1.15 129(23.8) 40(26.7)
≤1.15 413(76.2) 110(73.3)
LDL-C/HDL-C
≥2.55 297(54.8) 92(61.3)
<2.55 245(45.2) 58(38.7)
ApoB/ApoA-I
≥0.69 351(64.8) 106(70.7)
<0.69 191(35.2) 44(29.3)

*IQR: interquartile range; ECOG PS score: Eastern Cooperative Oncology Group performance status score; CEA: serum carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: apolipoprotein A-I; ApoB: apolipoprotein B; LDL-C/HDL-C: LDL-C to HDL-C ratio; ApoB/ApoA-I: ApoB to ApoA-I ratio.